FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767214532> ?p ?o ?g. }

• W2767214532 endingPage "S1793" @default.
• W2767214532 startingPage "S1793" @default.
• W2767214532 abstract "Nivolumab is a standard option for second-line treatment in pts with advanced NSCLC. Real-life data are lacking regarding the efficacy of nivolumab and post-nivolumab treatment. This analysis included the first 600 consecutive pts with stage IIIB/IV NSCLC who received ≥1 dose of nivolumab 3mg/kg q2w through the French EAP from 01/2015 for Squamous (Sq) and 06/2015 for Non-Sq NSCLC, until 08/2015. Median age was 64 yo, there were 409 (68%) men, 521 (87%) smokers, 478 (80%) PS0/1 pts, 230 (38%) Sq and 370 (62%) Non-Sq NSCLC, 130 (22%) pts with brain metastases. Nivolumab was administered as 2nd/3rd/≥4th-line for 26%/33%/41% pts, respectively. Best response was PR/SD/PD for 17%/30%/37% of patients, respectively, with 16% not assessable. Toxicities occurred in 187 (31%) pts, including 10% grade ≥3 events. After a median follow-up of 22.1 (95% CI 21.6-22.6) months, median PFS and OS from the initiation of nivolumab were 2.1 (95%CI 1.9-2.3) and 9.5 (95%CI 8.4-10.8) months, respectively. In the 92 pts with PS2 at initiation of nivolumab, PR/SD rates were 7%/28%; median OS was 3.6 (95%CI 2.7-5.2) months. A total of 130 pts had brain metastases at initiation of nivolumab: PR/SD rates were 12%/25%; median OS was 6.6 (95%CI 3.8-8.3) months. Post-nivolumab treatment was administered to 262 (44%) pts, and mostly consisted of gemcitabine (19%), docetaxel (18%), paclitaxel (14%), erlotinib (12%), vinorelbine (9%), platin-based doublet (8%), or pemetrexed (8%). Access to post-nivolumab treatment was higher in PS0/1 vs. PS2 pts (48% vs. 23%, p<0.001), but was not different according to histology or treatment line or disease control with nivolumab. Best response to post-nivolumab treatment was PR/SD/PD for 15%/42%/42% of pts, respectively. In the whole cohort, median post-nivolumab OS was 4.0 (95%CI 2.8-4.6) months, and was significantly higher in case of PR to nivolumab (HR=0.38; 95%CI 0.23-0.64; p<0.001), and if subsequent treatment was delivered (HR=0.30; 95%CI 0.24-0.38; p<0.001); median post-nivolumab OS in pts receiving post-nivolumab treatment was 7.5 (95%CI 6.8-8.7) months, and did not differ based on histology or treatment line. Efficacy and safety of nivolumab was in line with available data. Post-nivolumab treatment may be delivered in many pts, including pts with PS2 and brain metastases, with favorable impact on response and OS. Data on the whole cohort of 900 pts enrolled in the EAP will be presented." @default.
• W2767214532 created "2017-11-17" @default.
• W2767214532 creator A5002994604 @default.
• W2767214532 creator A5003268119 @default.
• W2767214532 creator A5005673716 @default.
• W2767214532 creator A5022856335 @default.
• W2767214532 creator A5023794502 @default.
• W2767214532 creator A5027068255 @default.
• W2767214532 creator A5029652258 @default.
• W2767214532 creator A5030455508 @default.
• W2767214532 creator A5033020627 @default.
• W2767214532 creator A5047402540 @default.
• W2767214532 creator A5050464038 @default.
• W2767214532 creator A5052251865 @default.
• W2767214532 creator A5060290892 @default.
• W2767214532 creator A5073425557 @default.
• W2767214532 creator A5074670245 @default.
• W2767214532 creator A5075914427 @default.
• W2767214532 creator A5077305357 @default.
• W2767214532 creator A5084444201 @default.
• W2767214532 creator A5087836238 @default.
• W2767214532 creator A5090329560 @default.
• W2767214532 date "2017-11-01" @default.
• W2767214532 modified "2023-09-27" @default.
• W2767214532 title "OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)" @default.
• W2767214532 doi "https://doi.org/10.1016/j.jtho.2017.09.430" @default.
• W2767214532 hasPublicationYear "2017" @default.
• W2767214532 type Work @default.
• W2767214532 sameAs 2767214532 @default.
• W2767214532 citedByCount "32" @default.
• W2767214532 countsByYear W27672145322018 @default.
• W2767214532 countsByYear W27672145322019 @default.
• W2767214532 countsByYear W27672145322020 @default.
• W2767214532 countsByYear W27672145322021 @default.
• W2767214532 countsByYear W27672145322022 @default.
• W2767214532 countsByYear W27672145322023 @default.
• W2767214532 crossrefType "journal-article" @default.
• W2767214532 hasAuthorship W2767214532A5002994604 @default.
• W2767214532 hasAuthorship W2767214532A5003268119 @default.
• W2767214532 hasAuthorship W2767214532A5005673716 @default.
• W2767214532 hasAuthorship W2767214532A5022856335 @default.
• W2767214532 hasAuthorship W2767214532A5023794502 @default.
• W2767214532 hasAuthorship W2767214532A5027068255 @default.
• W2767214532 hasAuthorship W2767214532A5029652258 @default.
• W2767214532 hasAuthorship W2767214532A5030455508 @default.
• W2767214532 hasAuthorship W2767214532A5033020627 @default.
• W2767214532 hasAuthorship W2767214532A5047402540 @default.
• W2767214532 hasAuthorship W2767214532A5050464038 @default.
• W2767214532 hasAuthorship W2767214532A5052251865 @default.
• W2767214532 hasAuthorship W2767214532A5060290892 @default.
• W2767214532 hasAuthorship W2767214532A5073425557 @default.
• W2767214532 hasAuthorship W2767214532A5074670245 @default.
• W2767214532 hasAuthorship W2767214532A5075914427 @default.
• W2767214532 hasAuthorship W2767214532A5077305357 @default.
• W2767214532 hasAuthorship W2767214532A5084444201 @default.
• W2767214532 hasAuthorship W2767214532A5087836238 @default.
• W2767214532 hasAuthorship W2767214532A5090329560 @default.
• W2767214532 hasBestOaLocation W27672145321 @default.
• W2767214532 hasConcept C121608353 @default.
• W2767214532 hasConcept C126322002 @default.
• W2767214532 hasConcept C141071460 @default.
• W2767214532 hasConcept C143998085 @default.
• W2767214532 hasConcept C146357865 @default.
• W2767214532 hasConcept C151730666 @default.
• W2767214532 hasConcept C2776256026 @default.
• W2767214532 hasConcept C2777701055 @default.
• W2767214532 hasConcept C2779177807 @default.
• W2767214532 hasConcept C2780030458 @default.
• W2767214532 hasConcept C71924100 @default.
• W2767214532 hasConcept C81729549 @default.
• W2767214532 hasConcept C86803240 @default.
• W2767214532 hasConcept C90924648 @default.
• W2767214532 hasConceptScore W2767214532C121608353 @default.
• W2767214532 hasConceptScore W2767214532C126322002 @default.
• W2767214532 hasConceptScore W2767214532C141071460 @default.
• W2767214532 hasConceptScore W2767214532C143998085 @default.
• W2767214532 hasConceptScore W2767214532C146357865 @default.
• W2767214532 hasConceptScore W2767214532C151730666 @default.
• W2767214532 hasConceptScore W2767214532C2776256026 @default.
• W2767214532 hasConceptScore W2767214532C2777701055 @default.
• W2767214532 hasConceptScore W2767214532C2779177807 @default.
• W2767214532 hasConceptScore W2767214532C2780030458 @default.
• W2767214532 hasConceptScore W2767214532C71924100 @default.
• W2767214532 hasConceptScore W2767214532C81729549 @default.
• W2767214532 hasConceptScore W2767214532C86803240 @default.
• W2767214532 hasConceptScore W2767214532C90924648 @default.
• W2767214532 hasIssue "11" @default.
• W2767214532 hasLocation W27672145321 @default.
• W2767214532 hasOpenAccess W2767214532 @default.
• W2767214532 hasPrimaryLocation W27672145321 @default.
• W2767214532 hasRelatedWork W2544577077 @default.
• W2767214532 hasRelatedWork W2560806959 @default.
• W2767214532 hasRelatedWork W2760957248 @default.
• W2767214532 hasRelatedWork W2767810851 @default.
• W2767214532 hasRelatedWork W2811002705 @default.
• W2767214532 hasRelatedWork W2898071776 @default.
• W2767214532 hasRelatedWork W2904759734 @default.
• W2767214532 hasRelatedWork W3097428643 @default.

• next